The Latest
Antengene Publishes Preclinical Research Paper On CD73 Small Molecule Inhibitor ATG-037 Combined With Selinexor In Cancer Gene Therapy
Antengene releases preclinical research on ATG-037, a small molecule targeting CD73, combined with selinexor for cancer therapy, highlighting potential new treatments.